Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Paying $2 Bil. For ImClone C225; New Milestone For Inlicensing Deals?

Executive Summary

Bristol-Myers Squibb's $2 bil. investment in ImClone's anti-cancer monoclonal antibody C225 (cetuximab) represents a $500 mil. premium to the company's estimate of the peak annual sales potential for the agent.

You may also be interested in...



GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D

GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts

GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D

GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts

Pharma Faces Phase III Licensing Drought; Separate R&D “Pools” May Help

Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested

Related Content

UsernamePublicRestriction

Register

PS038525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel